Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives

Z. Kaló, ZI. Petykó, FU. Fricke, N. Maniadakis, T. Tesař, K. Podrazilová, J. Espin, A. Inotai

. 2021 ; 19 (1) : 42. [pub] 20210715

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024368

Grantová podpora
Medicines for Europe Medicines for Europe

BACKGROUND: A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessment processes across countries and to create incentives for manufacturers to invest into incremental innovation. However, this can be impactful only if the framework can be adapted to heterogeneous health care financing systems in different jurisdictions, and the cost of evidence generation necessitated by the framework takes into account the anticipated benefits for the health care system and rewards for the developers. AREAS COVERED: The framework could potentially improve the pricing and reimbursement decisions of VAMs by adapting it to different country specific decision-contexts such as deliberative processes, augmented cost-effectiveness frameworks or formal multi-criteria decision analysis (MCDA); alternatively, some of its domains may be added to current general evaluation frameworks of medicines. The proposed evaluation framework may provide a starting point for practices based on which VAMs can be exempted from generic pricing mechanisms or can be integrated into the reimbursement and procurement system, allowing for price differentiation according to their added value. Besides evidence from RCTs, pricing and reimbursement decision processes of VAMs should allow for ex-ante non-RCT evidence for certain domains. Alternatively, relying on ex-post evidence agreements-such as outcome guarantee or coverage with evidence development-can also reduce decision uncertainty. CONCLUSIONS: The core evaluation framework for VAMs could trigger changes in the existing pricing, reimbursement and procurement practices by improving the appraisal of the added value created by incremental innovation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024368
003      
CZ-PrNML
005      
20211013133946.0
007      
ta
008      
211006s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12962-021-00296-2 $2 doi
035    __
$a (PubMed)34266465
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Kaló, Zoltán $u Center for Health Technology Assessment, Semmelweis University, Üllői rd. 25, 1085, Budapest, Hungary $u Pharmaceutical Policy Research, Syreon Research Institute, Mexikói str. 65/A, 1142, Budapest, Hungary
245    10
$a Development of a core evaluation framework of value-added medicines: report 2 on pharmaceutical policy perspectives / $c Z. Kaló, ZI. Petykó, FU. Fricke, N. Maniadakis, T. Tesař, K. Podrazilová, J. Espin, A. Inotai
520    9_
$a BACKGROUND: A core evaluation framework that captures the health care and societal benefits of value added medicines (VAMs, also often called repurposed medicines) was proposed in Report 1, aiming to reduce the heterogeneity in value assessment processes across countries and to create incentives for manufacturers to invest into incremental innovation. However, this can be impactful only if the framework can be adapted to heterogeneous health care financing systems in different jurisdictions, and the cost of evidence generation necessitated by the framework takes into account the anticipated benefits for the health care system and rewards for the developers. AREAS COVERED: The framework could potentially improve the pricing and reimbursement decisions of VAMs by adapting it to different country specific decision-contexts such as deliberative processes, augmented cost-effectiveness frameworks or formal multi-criteria decision analysis (MCDA); alternatively, some of its domains may be added to current general evaluation frameworks of medicines. The proposed evaluation framework may provide a starting point for practices based on which VAMs can be exempted from generic pricing mechanisms or can be integrated into the reimbursement and procurement system, allowing for price differentiation according to their added value. Besides evidence from RCTs, pricing and reimbursement decision processes of VAMs should allow for ex-ante non-RCT evidence for certain domains. Alternatively, relying on ex-post evidence agreements-such as outcome guarantee or coverage with evidence development-can also reduce decision uncertainty. CONCLUSIONS: The core evaluation framework for VAMs could trigger changes in the existing pricing, reimbursement and procurement practices by improving the appraisal of the added value created by incremental innovation.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Petykó, Zsuzsanna Ida $u Center for Health Technology Assessment, Semmelweis University, Üllői rd. 25, 1085, Budapest, Hungary $u Pharmaceutical Policy Research, Syreon Research Institute, Mexikói str. 65/A, 1142, Budapest, Hungary
700    1_
$a Fricke, Frank-Ulrich $u Technische Hochschule Nürnberg, Nürnberg, Germany
700    1_
$a Maniadakis, Nikos $u Department of Public Health Policies, Sector of Health Systems and Policy, School of Public Health, University of West Attica, Athens, Greece
700    1_
$a Tesař, Tomáš $u Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University in Bratislava, Bratislava, Slovakia
700    1_
$a Podrazilová, Kateřina $u Association of Health Insurance Companies, Prague, Czech Republic
700    1_
$a Espin, Jaime $u Andalusian School of Public Health, Granada, Spain
700    1_
$a Inotai, András $u Center for Health Technology Assessment, Semmelweis University, Üllői rd. 25, 1085, Budapest, Hungary. andras.inotai@syreon.eu $u Pharmaceutical Policy Research, Syreon Research Institute, Mexikói str. 65/A, 1142, Budapest, Hungary. andras.inotai@syreon.eu
773    0_
$w MED00008219 $t Cost effectiveness and resource allocation : C/E $x 1478-7547 $g Roč. 19, č. 1 (2021), s. 42
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34266465 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20211006 $b ABA008
991    __
$a 20211013133943 $b ABA008
999    __
$a ind $b bmc $g 1708294 $s 1144865
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 19 $c 1 $d 42 $e 20210715 $i 1478-7547 $m Cost effectiveness and resource allocation $n Cost Eff Resour Alloc $x MED00008219
GRA    __
$a Medicines for Europe $p Medicines for Europe
LZP    __
$a Pubmed-20211006

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace